Published in Onkologie on June 01, 2003
Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis. Br J Cancer (2010) 0.89
Influence of genetic variants in type I interferon genes on melanoma survival and therapy. PLoS One (2012) 0.84
A randomised trial evaluating bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: an update. Ecancermedicalscience (2008) 0.80
The synthetic parasite-derived peptide GK1 increases survival in a preclinical mouse melanoma model. Cancer Biother Radiopharm (2013) 0.77
Mucosal malignant melanomas in head and neck surgery: a retrospective study of six patients and review of the literature. Oral Maxillofac Surg (2010) 0.75
NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut (2004) 4.39
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol (2004) 3.97
Epidemiology of invasive cutaneous melanoma. Ann Oncol (2009) 2.21
Melanoma risk in congenital melanocytic naevi: a systematic review. Br J Dermatol (2006) 1.69
Use of monoclonal antibodies (UCHL1, Ki-B3) against T and B cell antigens in routine paraffin-embedded skin biopsy specimens. J Am Acad Dermatol (1989) 1.38
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.36
Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.30
Staging of cutaneous melanoma. Ann Oncol (2009) 1.26
Role of intermolecular interactions on the electronic and geometric structure of a large pi-conjugated molecule adsorbed on a metal surface. Phys Rev Lett (2008) 1.26
A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res (2003) 1.24
Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. J Clin Oncol (1997) 1.20
Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol (2010) 1.20
Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann Oncol (2009) 1.18
Biomarkers in melanoma. Ann Oncol (2009) 1.17
Utility of adjuvant systemic therapy in melanoma. Ann Oncol (2009) 1.10
Small molecules and targeted therapies in distant metastatic disease. Ann Oncol (2009) 1.08
Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data. Br J Dermatol (2009) 1.01
Telomerase activity in melanocytic lesions: A potential marker of tumor biology. Am J Pathol (2000) 0.97
Analysis of RUNX1 binding site and RAPTOR polymorphisms in psoriasis: no evidence for association despite adequate power and evidence for linkage. J Med Genet (2005) 0.97
Eruptive vellus hair cysts and steatocystoma multiplex. variants of one entity? Br J Dermatol (1996) 0.96
Immunotherapy of distant metastatic disease. Ann Oncol (2009) 0.96
Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. Ann Oncol (2006) 0.96
Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2009) 0.95
Complete remission of a radio-resistant cutaneous angiosarcoma of the scalp by systemic treatment with liposomal doxorubicin. Br J Dermatol (2002) 0.94
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). Ann Oncol (2008) 0.91
Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas. Ann Oncol (2013) 0.91
Low prevalence of the intrinsic form of atopic dermatitis among adult patients. Allergy (2006) 0.90
Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma. Br J Dermatol (2014) 0.90
Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2008) 0.90
Smoking and alcohol intake in severely affected patients with psoriasis in Germany. Dermatology (2009) 0.89
Loss of leucocyte common antigen (CD45) on atypical lymphocytes in the localized but not disseminated type of Pagetoid reticulosis. Br J Dermatol (1991) 0.87
[Cutaneous side effects of EGFR inhibitors--appearance and management]. Dtsch Med Wochenschr (2010) 0.86
Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis. Allergy (2011) 0.85
Prospective, randomized controlled trial on Lactobacillus rhamnosus in infants with moderate to severe atopic dermatitis. Br J Dermatol (2006) 0.85
Coincident PTCH and BRCA1 germline mutations in a patient with nevoid basal cell carcinoma syndrome and familial breast cancer. J Invest Dermatol (2001) 0.85
[Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma]. Cancer Radiother (2003) 0.84
Ultraviolet-induced formation of micronuclei and sister chromatid exchange in cultured fibroblasts of patients with cutaneous malignant melanoma. Cancer Genet Cytogenet (1989) 0.84
Intraoral lesions associated with sebaceous nevus syndrome. J Cutan Pathol (2006) 0.84
Botulism in Canada: summary for 1984. Can Med Assoc J (1985) 0.84
Botulism in Canada--summary for 1987. Can Dis Wkly Rep (1988) 0.84
Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety. Br J Dermatol (2014) 0.84
Low-frequency ultrasound treatment of chronic venous leg ulcers in an outpatient therapy. Acta Derm Venereol (1997) 0.83
Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis. Br J Dermatol (2008) 0.83
Low dose versus medium dose UV-A1 treatment in severe atopic eczema. Acta Derm Venereol (1995) 0.82
Maintenance therapy in cutaneous T-cell lymphoma: who, when, what? Eur J Cancer (2007) 0.82
Enhancing the inhibitory effect of nicotinamide upon collagen II induced arthritis in mice using N-acetylcysteine. Inflammation (1999) 0.82
Micrographic surgery of skin cancer in German hospitals 2005-2006. J Eur Acad Dermatol Venereol (2011) 0.82
Autoantibodies against CD28 are associated with atopic diseases. Clin Exp Immunol (2006) 0.82
Elevated MIA serum levels are of relevance for management of metastasized malignant melanomas: results of a German multicenter study. J Invest Dermatol (2000) 0.81
Elevated serum levels of soluble adhesion molecules ICAM-1 and ELAM-1 in patients with severe atopic eczema and influence of UVA1 treatment. Dermatology (1995) 0.81
Effect of bilateral cryptorchidism on the in vitro transformation of progesterone by testicular tissue at different stages of sexual maturation. J Steroid Biochem (1979) 0.81
Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma. Eur J Surg Oncol (2006) 0.81
Up-to-date results on survival of patients with melanoma in Germany. Br J Dermatol (2012) 0.81
Sentinel node dissection delays recurrence and prolongs melanoma-related survival: an analysis of 673 patients from a single center with long-term follow-up. Ann Surg Oncol (2010) 0.80
The sebaceous nevus as part of the Schimmelpenning-Feuerstein-Mims Syndrome--an obvious phacomatosis first documented in 1927. J Cutan Pathol (2003) 0.79
[Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis]. Hautarzt (2002) 0.79
Nicotinamide and methionine reduce the liver toxic effect of methotrexate. Gen Pharmacol (1999) 0.79
Risk evaluation in cutaneous melanoma patients undergoing lymph node dissection: impact of POSSUM. Ann R Coll Surg Engl (2011) 0.79
Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients. Anticancer Res (2001) 0.79
Primary extracutaneous malignant melanoma: a comprehensive review with emphasis on treatment. Onkologie (2004) 0.78
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. Ann Oncol (2011) 0.78
Dermal fibroblasts from acute inflamed atopic dermatitis lesions display increased eotaxin/CCL11 responsiveness to interleukin-4 stimulation. Br J Dermatol (2011) 0.78
Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers? Dermatology (2010) 0.78
Constitutively increased micronuclei are predominantly caused by acentric fragments. Mutat Res (1991) 0.77
Diabetes mellitus in cancer patients treated with combination interleukin 2 and alpha-interferon. Cancer Biother (1995) 0.77
[Skin changes as a result of targeted therapies in oncology patients: cutaneous side effects of targeted therapies in oncology patients]. Hautarzt (2009) 0.77
Combined interferon-alpha and interleukin-2 as adjuvant treatment for melanoma. Lancet (1998) 0.77
Suppressed thyroid-stimulating hormone secretion in patients treated with interleukin-2 and interferon-alpha 2b for metastatic melanoma. Clin Investig (1994) 0.76
[Current aspects of adjuvant therapy of malignant melanoma]. Hautarzt (2010) 0.76
Remarkable remission of a follicular lymphoma treated with rituximab and polychemotherapy (CHOP). Clin Exp Dermatol (2003) 0.76
Enhancement of the effect of methotrexate on collagen II induced arthritis in mice by nicotinamide. Inflammation (1998) 0.76
Elevated serum-soluble ELAM-1 levels in patients with severe plaque-type psoriasis. Arch Dermatol Res (1994) 0.75
Use of a hydrocapillary dressing in the management of highly exuding ulcers: a comparative study. J Wound Care (2005) 0.75
[Topical immunomodulator against skin cancer. Does the cream replace the knife? (interview by Dr. Judith Neumaier)]. MMW Fortschr Med (2005) 0.75
[Congenital cerebriform nevus cell nevus on the occiput. Removal after tissue expander implantation]. Hautarzt (2001) 0.75
[Mucous membrane melanomas of the upper aerodigestive tract. An analysis of 34 cases]. Laryngorhinootologie (1997) 0.75
[Amelanotic malignant melanoma of the scalp clinically resembling a proliferating trichilemmal cyst]. Dtsch Med Wochenschr (2003) 0.75
[Chromosome instability in patients with malignant melanoma of the skin]. Onkologie (1989) 0.75
[Hazards of exposure to the sun]. Dtsch Med Wochenschr (1994) 0.75
Ultraviolet-induced chromosomal instability in cultured fibroblasts of heterozygote carriers for xeroderma pigmentosum. Cancer Genet Cytogenet (1989) 0.75
Paraneoplastic bullous pemphigoid resembling erythema gyratum repens. Br J Dermatol (1999) 0.75
Elevated frequencies of micronuclei in cultured fibroblasts after freezing and thawing. Mutat Res (1990) 0.75
Discrimination between immunoaccessory and phagocytic monocytes/macrophages of the skin in paraffin-embedded tissue by the monoclonal antibody Ki-M1P. Br J Dermatol (1993) 0.75
[Adjuvant systemic treatment of melanoma]. Hautarzt (2011) 0.75
Malignant melanoma and Wiedemann-Beckwith syndrome in childhood. Klin Padiatr (2010) 0.75
[Malignant melanoma of the uvula and soft palate]. Hautarzt (2005) 0.75
[Malignant melanoma in adolescents]. Dtsch Med Wochenschr (1995) 0.75
Clinical evaluation of 5-S-cysteinyldopa testing using a new and optimized detection system as a tumour marker for malignant melanoma. Melanoma Res (2002) 0.75
Increased UV-induced sister-chromatid exchange in cultured fibroblasts of first-degree relatives of melanoma patients. Cancer Genet Cytogenet (1991) 0.75
[Lipoma of the lip. A rare differential diagnosis]. Hautarzt (2002) 0.75
Repeatable acute rhabdomyolysis with multiple organ dysfunction because of interferon alpha and dacarbazine treatment in metastatic melanoma. Br J Dermatol (2001) 0.75
[Immunmodulatory antibodies in the treatment of skin cancer]. Hautarzt (2008) 0.75
Clinicopathologic prognostic markers of survival: an analysis of 259 patients with malignant melanoma >or=1 mm. Tumour Biol (2009) 0.75
Increased mutagen sensitivity in human cultured fibroblasts with constitutively high micronucleus levels. Cancer Genet Cytogenet (1992) 0.75